Biliary cirrhosis is an immune mediated chronic liver disease, in which small bile ducts are inflamed or injured, due to the building-up of bile level. If left untreated, biliary cirrhosis can lead to liver failure. In this disease, the immune system becomes overactive and attacks healthy bile ducts. Some of the complications associated with biliary cirrhosis are high blood cholesterol level, fat soluble vitamin deficiencies, and osteoporosis. Some of the symptoms observed in patients with biliary cirrhosis are itchy skin, tiredness, weight loss, poor appetite, arthritis, and diarrhea. Novimmune SA is in the process of developing NI-0401 as a CD3 antigen inhibitor for the treatment of biliary cirrhosis. Some other companies involved in biliary cirrhosis pipeline are Medigene AG and Gilead Sciences Inc. among others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.